Mainz Biomed (MYNZ) Competitors $4.82 -0.14 (-2.82%) (As of 12/24/2024 05:19 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends MYNZ vs. ESLA, QTTB, CDIO, ACHL, PASG, ALRN, CASI, RLYB, SNYR, and JATTShould you be buying Mainz Biomed stock or one of its competitors? The main competitors of Mainz Biomed include Estrella Immunopharma (ESLA), Q32 Bio (QTTB), Cardio Diagnostics (CDIO), Achilles Therapeutics (ACHL), Passage Bio (PASG), Aileron Therapeutics (ALRN), CASI Pharmaceuticals (CASI), Rallybio (RLYB), Synergy CHC Corp. (Uplisting) (SNYR), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Mainz Biomed vs. Estrella Immunopharma Q32 Bio Cardio Diagnostics Achilles Therapeutics Passage Bio Aileron Therapeutics CASI Pharmaceuticals Rallybio Synergy CHC Corp. (Uplisting) JATT Acquisition Estrella Immunopharma (NASDAQ:ESLA) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, valuation, profitability, dividends, risk, media sentiment and institutional ownership. Is ESLA or MYNZ more profitable? Mainz Biomed's return on equity of 0.00% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -195.77% -157.28% Mainz Biomed N/A N/A N/A Does the media prefer ESLA or MYNZ? In the previous week, Mainz Biomed had 7 more articles in the media than Estrella Immunopharma. MarketBeat recorded 7 mentions for Mainz Biomed and 0 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.00 beat Mainz Biomed's score of -0.48 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Overall Sentiment Estrella Immunopharma Neutral Mainz Biomed Neutral Which has more volatility and risk, ESLA or MYNZ? Estrella Immunopharma has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Which has stronger earnings & valuation, ESLA or MYNZ? Estrella Immunopharma has higher earnings, but lower revenue than Mainz Biomed. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-4.50Mainz Biomed$917.20K10.52-$26.30M-$65.60-0.07 Does the MarketBeat Community believe in ESLA or MYNZ? Mainz Biomed received 13 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. CompanyUnderperformOutperformEstrella ImmunopharmaN/AN/AMainz BiomedOutperform Votes1372.22% Underperform Votes527.78% Do insiders and institutionals have more ownership in ESLA or MYNZ? 0.3% of Estrella Immunopharma shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend ESLA or MYNZ? Mainz Biomed has a consensus price target of $120.00, indicating a potential upside of 2,389.63%. Given Mainz Biomed's stronger consensus rating and higher possible upside, analysts clearly believe Mainz Biomed is more favorable than Estrella Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mainz Biomed 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryMainz Biomed beats Estrella Immunopharma on 8 of the 14 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Mainz Biomed News Delivered to You Automatically Sign up to receive the latest news and ratings for MYNZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYNZ vs. The Competition Export to ExcelMetricMainz BiomedPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.65M$6.71B$5.22B$9.25BDividend YieldN/A3.00%5.12%4.28%P/E Ratio-0.0710.6387.5417.27Price / Sales10.52196.091,166.59119.75Price / CashN/A57.1543.2337.83Price / Book0.455.164.834.93Net Income-$26.30M$151.58M$120.46M$225.34M7 Day Performance27.51%4.12%2.85%4.14%1 Month Performance-41.73%-3.99%19.70%1.15%1 Year Performance-89.96%10.32%30.57%16.98% Mainz Biomed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYNZMainz Biomed2.514 of 5 stars$4.82-2.8%$120.00+2,389.6%-90.0%$9.65M$917,203.00-0.0730ESLAEstrella Immunopharma0.1552 of 5 stars$1.17+0.9%N/A-3.2%$42.33MN/A-4.50N/AGap DownQTTBQ32 Bio2.4823 of 5 stars$3.46-3.6%$29.86+762.9%N/A$42.15M$-6,651,000.00-0.2439CDIOCardio Diagnostics2.5514 of 5 stars$1.01+3.7%$2.00+98.0%-55.5%$40.86M$20,000.000.007ACHLAchilles Therapeutics3.2319 of 5 stars$0.98flat$4.00+307.7%+39.0%$40.32MN/A-0.59250News CoveragePASGPassage Bio2.7639 of 5 stars$0.65-1.8%$7.75+1,096.0%-33.9%$40.03MN/A-0.55130Gap DownALRNAileron Therapeutics3.7591 of 5 stars$1.83+4.6%$19.00+938.3%-31.1%$39.65MN/A-0.599Positive NewsCASICASI Pharmaceuticals3.1398 of 5 stars$2.56-3.4%$6.00+134.4%-55.9%$39.58M$22.06M-1.15180Gap DownRLYBRallybio2.7749 of 5 stars$0.95flat$9.75+926.3%-67.5%$39.41M$598,000.00-0.5940SNYRSynergy CHC Corp. (Uplisting)N/A$4.52+0.4%N/AN/A$39.34M$26.01M0.0040JATTJATT AcquisitionN/A$2.28-2.6%N/A-56.7%$39.33MN/A0.003News CoverageHigh Trading Volume Related Companies and Tools Related Companies Estrella Immunopharma Alternatives Q32 Bio Alternatives Cardio Diagnostics Alternatives Achilles Therapeutics Alternatives Passage Bio Alternatives Aileron Therapeutics Alternatives CASI Pharmaceuticals Alternatives Rallybio Alternatives Synergy CHC Corp. (Uplisting) Alternatives JATT Acquisition Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MYNZ) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYNZ Stock Alerts